Molecule of the Month. PDGFR-alpha antagonist Gleevec reduces blood vessel leakage and increases the therapeutic window associated with tissue plasminogen activator stroke treatment.
Lewis
Jana A
JA
Vanderbilt University, Vanderbilt University Medical Center, Department of Pharmacology, Nashville, TN 37232-6600, USA.
D000818:Animals; D001549:Benzamides; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000473:pathology; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002536:Cerebral Arteries / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology*; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors*; D020521:Stroke / Q000188:drug therapy* / Q000473:pathology; D010959:Tissue Plasminogen Activator / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D017479:Receptors, Platelet-Derived Growth Factor; D010959:Tissue Plasminogen Activator